Genetic variant within CDK6 regulates immune response to palbociclib treatment.

doi:10.1016/j.clim.2021.108777

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic variant within CDK6 regulates immune response to palbociclib treatment.

Clinical immunology (Orlando, Fla.) - 1 Feb 2022

Serra Valentina, Orrù Valeria, Steri Maristella, Fiorillo Edoardo, Cucca Francesco, Zoledziewska Magdalena

Abstract excerpt

Everyone carries a set of genetic variants that contribute to regulation of the levels of blood cells, with unknown clinical impact. One of them, rs445 within the cell-cycle checkpoint gene CDK6, reduces the levels of myeloid cell types including granulocytes. We treated CD3+ T cells and whole blood with palbociclib in 41 individuals, who were stratified by genotype for analyses. In T cells we assessed cell cycle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to Cells, Cultured

Share to Cyclin-Dependent Kinase 6

Share to Gene Expression Regulation

Share to Piperazines

Share to Pyridines

Share to T-Lymphocytes

Source

Open in PubMed

Identifiers

PMID: 34116212
DOI: 10.1016/j.clim.2021.108777

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Genetic variant within CDK6 regulates immune response to palbociclib treatment.PMID 34116212Read ↗

Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Semantic proximity Read ↗

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.Semantic proximity Read ↗

Racial Disparities in Neutrophil Counts Among Patients with Metastatic Breast Cancer during Treatment with CDK4/6 InhibitorsSemantic proximity Read ↗

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.Semantic proximity Read ↗

Detection of functional single-nucleotide polymorphisms that affect apoptosis.Semantic proximity Read ↗

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.Semantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Single-Nucleotide Polymorphisms (SNPs) Can Predict the Efficacy and Toxicity of Cancer Immunotherapy? A Systematic ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.